Login to Your Account

Other News To Note

Tuesday, December 21, 2010
PDL BioPharma Inc., of Incline Village, Nev., said the U.S. Patent and Trademark Office terminated an interference proceeding initiated by UCB Pharma SA, of Brussels, Belgium, involving Crohn's disease drug Cimzia (certolizumab pegol), a tumor necrosis factor blocker.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription